GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » Asset Turnover

CNBX (CNBX Pharmaceuticals) Asset Turnover : 0.00 (As of Nov. 2024)


View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. CNBX Pharmaceuticals's Revenue for the three months ended in Nov. 2024 was $0.00 Mil. CNBX Pharmaceuticals's Total Assets for the quarter that ended in Nov. 2024 was $0.03 Mil. Therefore, CNBX Pharmaceuticals's Asset Turnover for the quarter that ended in Nov. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. CNBX Pharmaceuticals's annualized ROE % for the quarter that ended in Nov. 2024 was 5.45%. It is also linked to ROA % through Du Pont Formula. CNBX Pharmaceuticals's annualized ROA % for the quarter that ended in Nov. 2024 was -513.21%.


CNBX Pharmaceuticals Asset Turnover Historical Data

The historical data trend for CNBX Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals Asset Turnover Chart

CNBX Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.02 0.63 0.49

CNBX Pharmaceuticals Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.15 - - -

Competitive Comparison of CNBX Pharmaceuticals's Asset Turnover

For the Biotechnology subindustry, CNBX Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CNBX Pharmaceuticals's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's Asset Turnover falls into.



CNBX Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

CNBX Pharmaceuticals's Asset Turnover for the fiscal year that ended in Aug. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Aug. 2024 )/( (Total Assets (A: Aug. 2023 )+Total Assets (A: Aug. 2024 ))/ count )
=0.13/( (0.499+0.031)/ 2 )
=0.13/0.265
=0.49

CNBX Pharmaceuticals's Asset Turnover for the quarter that ended in Nov. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Nov. 2024 )/( (Total Assets (Q: Aug. 2024 )+Total Assets (Q: Nov. 2024 ))/ count )
=0/( (0.031+0.022)/ 2 )
=0/0.0265
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


CNBX Pharmaceuticals  (OTCPK:CNBX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

CNBX Pharmaceuticals's annulized ROE % for the quarter that ended in Nov. 2024 is

ROE %**(Q: Nov. 2024 )
=Net Income/Total Stockholders Equity
=-0.136/-2.497
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.136 / 0)*(0 / 0.0265)*(0.0265/ -2.497)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-0.0106
=ROA %*Equity Multiplier
=-513.21 %*-0.0106
=5.45 %

Note: The Net Income data used here is four times the quarterly (Nov. 2024) net income data. The Revenue data used here is four times the quarterly (Nov. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

CNBX Pharmaceuticals's annulized ROA % for the quarter that ended in Nov. 2024 is

ROA %(Q: Nov. 2024 )
=Net Income/Total Assets
=-0.136/0.0265
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-0.136 / 0)*(0 / 0.0265)
=Net Margin %*Asset Turnover
= %*0
=-513.21 %

Note: The Net Income data used here is four times the quarterly (Nov. 2024) net income data. The Revenue data used here is four times the quarterly (Nov. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


CNBX Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


CNBX Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.
Executives
Cannabics Inc. 10 percent owner 108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills director, officer: President, CEO, CFO
North American Mining Corp 10 percent owner 6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford director, officer: Vice-President, Secretary